I now have comprehensive information to provide a thorough clinical answer. Let me compile the full response.
Clinical Assessment: 47F with BP 180/120 - Known Hypertensive, Off Medication
Step 1: Classify the Presentation
The first critical task is distinguishing hypertensive urgency from hypertensive emergency.
| Feature | Hypertensive Urgency | Hypertensive Emergency |
|---|
| BP level | >180/120 mm Hg | >180/120 mm Hg |
| Target organ damage | Absent | Present |
| Treatment setting | Outpatient/ED, oral agents | ICU, IV agents |
| Speed of BP reduction | Hours to days | Minutes to hours |
"A hypertensive emergency is the combination of elevated BP levels and signs or symptoms of acute, ongoing, target organ damage. A severe elevation in blood pressure without evidence of target organ damage is considered a hypertensive urgency." - Brenner & Rector's The Kidney / Lippincott Pharmacology
Step 2: Immediate Evaluation (History + Exam)
Symptoms to actively ask about:
- Headache, visual changes, altered sensorium, seizures (hypertensive encephalopathy / stroke)
- Chest pain, dyspnea, orthopnea (ACS, acute heart failure)
- Back pain (aortic dissection)
- Oliguria, hematuria (hypertensive nephropathy / TMA)
- Nausea/vomiting (raised ICP)
Physical exam essentials:
- Fundoscopy - look for hemorrhages, exudates, papilledema
- Neurological status - focal deficits, altered consciousness
- Cardiac and pulmonary exam - S3, pulmonary crackles
- Radial-femoral pulse delay (aortic dissection)
- Bruits - abdominal (renal artery stenosis), carotid
Step 3: Investigations
Mandatory in all cases:
| Test | Purpose |
|---|
| ECG | Ischemia, LVH, arrhythmia |
| Chest X-ray | Pulmonary edema, cardiomegaly, aortic knuckle |
| Urine dipstick + microscopy | Proteinuria, hematuria, RBC casts |
| Serum creatinine / eGFR | Renal impairment |
| Blood glucose, electrolytes | Baseline, exclude secondary causes |
| CBC | Microangiopathic hemolytic anemia (TMA) |
If clinically indicated:
- CT/MRI brain (neurological symptoms, suspected stroke/hemorrhage)
- Echocardiography (suspected acute HF or dissection)
- Thoracoabdominal CT/MRI (suspected aortic dissection)
- Renal Doppler (suspected renovascular disease)
Step 4: Management
Scenario A: Hypertensive URGENCY (no target organ damage - most likely in this patient)
This patient - known hypertensive off medication, asymptomatic with BP 180/120 - most likely has hypertensive urgency.
Key principle: No proven benefit from rapid BP reduction in asymptomatic patients without target organ damage. Aggressive lowering can cause ischemic damage.
Immediate measures:
- Place in a quiet room and allow to rest - a simple rest period alone reduces BP by ≥20/10 in ~1/3 of patients (an RCT showed rest = telmisartan 40 mg over 2 hours)
- Oral antihypertensive therapy - restart/initiate long-acting agents
- Target: Reduce BP to <160/100 mm Hg over 2-4 hours, then normalize over days
Oral drug choices for urgency:
| Drug | Dose | Notes |
|---|
| Captopril | 25 mg oral/sublingual | Onset ~15-30 min; good first choice |
| Labetalol | 200-400 mg oral | Alpha + beta blockade; avoid in asthma |
| Clonidine | 0.1-0.2 mg oral | Rebound hypertension risk if stopped abruptly |
| Amlodipine | 5-10 mg oral | For initiating long-term therapy |
"The most important aspect of treatment of hypertensive urgency is not achieving a BP goal but rather ensuring adequate follow-up, generally within 1 week, to optimize care and improve chronic BP control." - Comprehensive Clinical Nephrology
Do NOT use: Sublingual nifedipine - causes unpredictable BP fall that may precipitate cerebral ischemia (shunts blood from penumbra).
Scenario B: Hypertensive EMERGENCY (if target organ damage present)
Admit to ICU. IV therapy. Continuous hemodynamic monitoring.
BP reduction targets (ACC/AHA 2017):
- Reduce MAP by no more than 25% in the first hour
- Bring to ~160/100-160/110 over next 2-6 hours
- Normalize over next 24-48 hours
- (Washington Manual: reduce MAP by 10-20% in first hour, then 5-15% over next 23 hours)
Key IV agents by scenario:
| Clinical Scenario | Preferred Agent(s) |
|---|
| General hypertensive emergency | Nicardipine, labetalol, clevidipine |
| Aortic dissection | Esmolol + nitroprusside/nicardipine (SBP <120 within 20 min) |
| Hypertensive encephalopathy | Labetalol, nicardipine |
| ACS / acute HF | Nitroglycerin, esmolol |
| Acute stroke (ischemic) | Only lower if BP >220/120 (avoid aggressive reduction) |
| Intracranial hemorrhage | Nicardipine; SBP target <140 |
| Eclampsia | Hydralazine, labetalol, nicardipine |
| Pheochromocytoma crisis | Phentolamine (alpha-blocker); avoid beta-blockers alone |
"Abrupt or excessive BP lowering may cause or contribute to cerebral, coronary, or renal ischemia." - Comprehensive Clinical Nephrology
Volume status: Many patients with hypertensive emergency are volume depleted due to pressure natriuresis - avoid diuretics unless pulmonary edema is present.
Step 5: Long-Term Plan (this patient)
This 47-year-old is a known hypertensive who stopped her medications - the primary issue is non-adherence/non-compliance.
- Initiate or resume oral antihypertensives - first-line options:
- ACE inhibitor (e.g., ramipril 5-10 mg/day) or ARB
- Calcium channel blocker (e.g., amlodipine 5 mg/day)
- Thiazide diuretic if needed as combination
- Address reasons for medication non-compliance (side effects, cost, understanding)
- Lifestyle modifications:
- DASH diet (low sodium <2.3 g/day)
- Weight reduction
- Aerobic exercise 30 min/day
- Limit alcohol
- Smoking cessation if applicable
- Follow-up within 1 week to reassess BP and adherence
- Screen for secondary hypertension if BP remains difficult to control
Summary
| Priority | Action |
|---|
| Immediate | Assess for target organ damage (symptoms, fundoscopy, neuro exam) |
| Investigations | ECG, CXR, urinalysis, creatinine, CBC |
| If urgency | Rest, oral captopril/labetalol, outpatient follow-up in 1 week |
| If emergency | ICU admission, IV nicardipine or labetalol, max 25% MAP reduction in 1st hour |
| Long-term | Restart antihypertensives, address non-compliance, lifestyle changes |
Sources: Comprehensive Clinical Nephrology 7th Ed.; Brenner & Rector's The Kidney; Lippincott Illustrated Reviews Pharmacology; The Washington Manual of Medical Therapeutics